Sarepta Therapeutics (SRPT) Financials

$37.23 -1.12 (-2.92%)

Closing price 04:00 PM Eastern

Extended Trading

$37.38 +0.15 (+0.41%)

As of 06:35 PM Eastern

Annual Income Statements for Sarepta Therapeutics

This table shows Sarepta Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	235	-536	-703	-419	-554	-715	-362	-51	-267	-220
Consolidated Net Income / (Loss)	235	-536	-703	-419	-554	-715	-362	-51	-267	-220
Net Income / (Loss) Continuing Operations	235	-536	-703	-419	-554	-715	-362	-51	-267	-220
Total Pre-Tax Income	261	-520	-690	-419	-553	-714	-363	-49	-267	-220
Total Operating Income	218	-268	-536	-460	-564	-706	-344	-172	-267	-220
Total Gross Profit	1,902	1,243	933	702	540	381	301	155	5.42	1.25
Total Revenue	1,902	1,243	933	702	540	381	301	155	5.42	1.25
Operating Revenue	1,902	1,243	933	702	540	381	301	155	5.42	1.25
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	1,684	1,511	1,469	1,162	1,104	1,086	645	326	272	221
Selling, General & Admin Expense	558	482	451	283	318	285	208	123	84	75
Research & Development Expense	805	877	877	771	722	734	402	167	188	146
Amortization Expense	2.41	1.56	0.71	0.71	0.66	0.85	0.87	1.05	0.03	-
Other Operating Expenses / (Income)	319	150	140	107	63	67	34	36	0.10	-
Total Other Income / (Expense), net	43	-252	-154	41	11	-8.32	-19	123	-0.54	0.15
Interest Expense	0.00	387	125	0.00	0.00	-	-	-	-	-
Other Income / (Expense), net	43	135	-28	41	11	-8.32	-19	123	-0.54	0.15
Income Tax Expense	26	16	14	-0.17	1.06	1.20	-0.69	2.06	-	-
Basic Earnings per Share	$2.47	($5.80)	($8.03)	($5.15)	($7.11)	($9.71)	($5.46)	($0.86)	($5.49)	($5.20)
Weighted Average Basic Shares Outstanding	95.08M	92.40M	87.56M	81.26M	77.96M	73.62M	66.25M	58.82M	48.70M	42.29M
Diluted Earnings per Share	$2.34	($5.80)	($8.03)	($5.15)	($7.11)	($9.71)	($5.46)	($0.86)	($5.49)	($5.20)
Weighted Average Diluted Shares Outstanding	107.88M	92.40M	87.56M	81.26M	77.96M	73.62M	66.25M	58.82M	48.70M	42.29M
Weighted Average Basic & Diluted Shares Outstanding	97.03M	93.86M	87.98M	81.26M	77.96M	73.62M	66.25M	58.82M	48.70M	42.29M

This table shows Sarepta Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-448	156	37	6.12	36	46	-41	-25	-517	-143	-258
Consolidated Net Income / (Loss)	-448	159	34	6.46	36	46	-41	-24	-517	-109	-258
Net Income / (Loss) Continuing Operations	-448	159	34	6.46	36	46	-41	-24	-517	-143	-258
Total Pre-Tax Income	-384	172	34	14	41	40	-33	-15	-513	-101	-256
Total Operating Income	-300	162	22	-0.70	35	25	-21	-134	-138	-107	-131
Total Gross Profit	745	658	467	363	413	397	332	261	254	258	230
Total Revenue	745	658	467	363	413	397	332	261	254	258	230
Operating Revenue	745	658	467	363	413	397	332	261	254	258	230
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	1,045	497	445	364	379	372	353	395	392	365	362
Selling, General & Admin Expense	134	164	128	139	127	132	121	119	111	120	105
Research & Development Expense	773	200	224	180	200	196	194	242	246	214	217
Amortization Expense	0.60	0.60	0.60	0.60	0.60	0.76	0.44	0.18	0.18	0.18	0.18
Other Operating Expenses / (Income)	138	132	92	45	51	44	37	34	35	31	40
Total Other Income / (Expense), net	-83	10	12	14	6.54	16	-12	119	-375	-29	-125
Other Income / (Expense), net	-83	10	12	14	6.54	16	-12	119	13	-	0.00
Income Tax Expense	64	13	0.40	7.12	5.33	-5.28	7.76	9.36	4.05	7.94	1.32
Basic Earnings per Share	($4.60)	$1.67	$0.35	$0.07	$0.38	$0.79	($0.46)	($0.27)	($5.86)	($1.24)	($2.94)
Weighted Average Basic Shares Outstanding	97.36M	95.08M	95.39M	94.62M	93.99M	92.40M	88.89M	88.74M	88.19M	87.56M	87.63M
Diluted Earnings per Share	($4.60)	$1.56	$0.34	$0.07	$0.37	$0.79	($0.46)	($0.27)	($5.86)	($1.24)	($2.94)
Weighted Average Diluted Shares Outstanding	97.36M	107.88M	100.45M	99.14M	99.11M	92.40M	88.89M	88.74M	88.19M	87.56M	87.63M
Weighted Average Basic & Diluted Shares Outstanding	98.28M	97.03M	95.52M	95.37M	94.52M	93.86M	93.55M	93.28M	93.15M	87.98M	87.78M

This table details how cash moves in and out of Sarepta Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	675	-542	-1,140	614	668	473	-229	477	42	6.75
Net Cash From Operating Activities	-206	-501	-325	-443	107	-456	-389	-232	-246	-149
Net Cash From Continuing Operating Activities	-206	-501	-325	-443	107	-456	-389	-232	-246	-149
Net Income / (Loss) Continuing Operations	235	-536	-703	-419	-554	-715	-362	-51	-267	-220
Consolidated Net Income / (Loss)	235	-536	-703	-419	-554	-715	-362	-51	-267	-220
Depreciation Expense	38	44	42	38	27	25	12	8.09	5.61	5.25
Non-Cash Adjustments To Reconcile Net Income	49	459	418	36	81	301	77	-78	32	33
Changes in Operating Assets and Liabilities, net	-528	-469	-82	-98	554	-67	-108	-110	-16	32
Net Cash From Investing Activities	756	-166	-1,047	495	-122	287	-370	-179	-90	8.41
Net Cash From Continuing Investing Activities	756	-166	-1,047	495	-122	287	-370	-179	-90	8.41
Purchase of Property, Plant & Equipment	-137	-76	-31	-38	-82	-60	-61	-12	-5.34	-3.40
Acquisitions	-10	-11	-1.43	-2.31	-	-173	0.00	-9.22	-1.53	-1.43
Purchase of Investments	-1,100	-2,049	-1,938	-32	-1,334	-1,194	-1,172	-590	-195	-173
Divestitures	0.00	102	0.00	102	108	0.00	0.00	125	-	-
Sale and/or Maturity of Investments	2,002	1,868	923	466	1,189	1,716	866	307	112	186
Net Cash From Financing Activities	125	125	233	562	682	643	530	888	378	148
Net Cash From Continuing Financing Activities	125	125	233	562	682	643	530	888	378	148
Repayment of Debt	-0.07	0.00	-576	0.00	0.00	-0.69	-269	-55	-2.60	-3.00
Repurchase of Preferred Equity	0.00	0.00	-248	0.00	0.00	-	-	-	-	-
Issuance of Debt	0.00	-6.89	1,127	0.00	291	246	236	640	-	20
Other Financing Activities, net	125	132	-71	13	79	32	50	-51	-5.00	11
Cash Interest Paid	16	16	44	56	34	8.55	11	1.91	1.56	0.77
Cash Income Taxes Paid	23	15	1.70	0.58	2.51	0.93	1.55	5.34	-	-

This table details how cash moves in and out of Sarepta Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-862	905	-186	-44	-1.14	-117	-310	-20	-95	-72	171
Net Cash From Operating Activities	-583	92	-71	15	-242	-55	-115	-122	-209	-92	-65
Net Cash From Continuing Operating Activities	-583	92	-71	15	-242	-53	-116	-122	-209	-92	-65
Net Income / (Loss) Continuing Operations	-448	159	34	6.46	36	46	-41	-24	-517	-109	-258
Consolidated Net Income / (Loss)	-448	159	34	6.46	36	46	-41	-24	-517	-109	-258
Depreciation Expense	9.98	10	9.81	8.72	8.74	11	11	11	11	11	11
Non-Cash Adjustments To Reconcile Net Income	207	94	70	-13	-102	19	75	-53	418	100	172
Changes in Operating Assets and Liabilities, net	-353	-172	-184	13	-185	-130	-161	-56	-122	-94	9.99
Net Cash From Investing Activities	-291	764	-129	-99	219	-64	-211	97	12	9.80	19
Net Cash From Continuing Investing Activities	-291	764	-129	-99	219	-64	-211	97	12	9.80	19
Purchase of Property, Plant & Equipment	-44	-38	-37	-29	-32	-19	-30	-18	-9.49	-7.96	-8.23
Acquisitions	-2.24	-	-	-	-10	-	-11	-0.05	-0.09	-0.20	-
Purchase of Investments	-286	-163	-389	-331	-216	-574	-646	-403	-427	-429	-372
Sale and/or Maturity of Investments	41	965	298	261	478	528	476	416	449	447	400
Net Cash From Financing Activities	12	49	14	40	22	1.94	15	5.86	102	11	216
Net Cash From Continuing Financing Activities	12	49	14	40	22	1.94	15	5.86	102	11	216
Other Financing Activities, net	12	49	14	40	22	8.83	15	5.86	102	11	-88
Cash Interest Paid	7.19	0.69	7.19	0.79	7.19	0.79	7.31	0.79	7.02	3.15	13
Cash Income Taxes Paid	0.84	11	3.62	7.08	0.91	5.51	3.58	5.46	0.54	0.34	-

This table presents Sarepta Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	3,963	3,265	3,128	3,148	2,985	1,823	1,642	1,308	424	274
Total Current Assets	3,073	2,579	2,558	2,604	2,485	1,469	1,426	1,229	373	225
Cash & Equivalents	1,103	428	967	2,116	1,503	835	371	600	122	80
Short-Term Investments	252	1,248	1,023	0.00	436	290	803	479	195	112
Accounts Receivable	602	400	215	153	101	91	49	29	5.23	3.98
Inventories, net	750	323	204	186	232	171	125	84	13	-
Prepaid Expenses	276	102	-	-	-	-	-	-	-	-
Other Current Assets	90	78	150	149	213	82	78	37	27	17
Plant, Property, & Equipment, net	340	227	180	191	190	130	97	43	38	37
Total Noncurrent Assets	549	458	390	353	309	224	119	36	13	12
Long-Term Investments	133	0.00	-	-	-	-	-	22	4.75	0.78
Other Noncurrent Operating Assets	416	458	390	338	295	212	107	-	-	4.47
Total Liabilities & Shareholders' Equity	3,963	3,265	3,128	3,148	2,985	1,823	1,642	1,308	424	274
Total Liabilities	2,435	2,405	2,743	2,220	2,223	1,005	610	519	87	83
Total Current Liabilities	732	654	620	453	416	265	174	88	75	62
Short-Term Debt	0.00	105	0.00	-	-	-	-	6.18	10	8.43
Accounts Payable	214	165	96	77	111	68	34	8.47	30	20
Accrued Expenses	374	315	419	272	194	186	134	69	31	29
Current Deferred Revenue	130	50	89	89	89	3.30	-	3.32	3.30	3.30
Other Current Liabilities	13	18	15	15	22	7.84	5.77	1.39	1.31	1.28
Total Noncurrent Liabilities	1,704	1,752	2,124	1,767	1,143	740	436	430	12	21
Long-Term Debt	1,137	1,133	1,544	1,097	992	682	421	425	6.04	15
Noncurrent Deferred Revenue	325	437	485	574	0.00	0.00	-	-	-	-
Other Noncurrent Operating Liabilities	242	182	95	96	151	58	16	5.54	5.95	6.17
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,528	859	385	928	762	818	1,032	789	337	190
Total Preferred & Common Equity	1,528	859	385	928	762	818	1,032	789	337	190
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,528	859	385	928	762	818	1,032	789	337	190
Common Stock	5,739	5,305	4,297	4,135	3,610	3,112	2,611	2,007	1,503	1,090
Retained Earnings	-4,211	-4,446	-3,910	-3,207	-2,848	-2,294	-1,579	-1,217	-1,166	-899
Accumulated Other Comprehensive Income / (Loss)	-0.22	0.92	-1.66	-0.02	0.00	0.05	-0.10	-0.38	-0.12	-0.11

This table presents Sarepta Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	3,465	3,600	3,424	3,224	3,110	3,126	3,060	3,156
Total Current Assets	2,433	2,685	2,684	2,465	2,451	2,473	2,488	2,626
Cash & Equivalents	241	198	384	427	542	852	872	1,039
Short-Term Investments	282	1,001	1,077	963	1,192	1,009	1,010	1,034
Accounts Receivable	659	435	360	379	319	237	224	202
Inventories, net	941	566	486	374	244	227	203	221
Prepaid Expenses	203	321	303	239	-	-	-	-
Other Current Assets	105	165	75	83	154	148	180	131
Plant, Property, & Equipment, net	361	306	276	249	212	189	183	181
Total Noncurrent Assets	672	609	464	510	446	464	389	349
Long-Term Investments	263	182	-	-	-	-	-	-
Other Noncurrent Operating Assets	409	427	464	510	446	464	389	336
Total Liabilities & Shareholders' Equity	3,465	3,600	3,424	3,224	3,110	3,126	3,060	3,156
Total Liabilities	2,323	2,379	2,347	2,263	2,345	2,384	2,347	2,725
Total Current Liabilities	606	699	688	609	451	499	537	603
Short-Term Debt	0.00	92	92	106	-	-	-	-
Accounts Payable	156	119	107	92	88	110	107	118
Accrued Expenses	392	345	350	283	322	327	346	369
Current Deferred Revenue	45	127	122	112	22	45	67	89
Other Current Liabilities	13	17	17	16	18	17	17	26
Total Noncurrent Liabilities	1,717	1,679	1,659	1,654	1,895	1,886	1,810	2,122
Long-Term Debt	1,138	1,136	1,135	1,134	1,237	1,236	1,234	1,543
Noncurrent Deferred Revenue	325	325	325	325	485	485	485	507
Other Noncurrent Operating Liabilities	254	218	199	196	173	165	91	72
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	1,143	1,221	1,077	961	764	741	713	431
Total Preferred & Common Equity	1,143	1,221	1,077	961	764	741	713	431
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	1,143	1,221	1,077	961	764	741	713	431
Common Stock	5,801	5,589	5,482	5,372	5,257	5,193	5,140	4,235
Retained Earnings	-4,658	-4,370	-4,404	-4,410	-4,492	-4,451	-4,427	-3,801
Accumulated Other Comprehensive Income / (Loss)	0.03	2.25	-1.03	-0.69	-0.64	-1.06	-0.42	-3.21

This table displays calculated financial ratios and metrics derived from Sarepta Therapeutics' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	52.97%	33.26%	32.93%	29.96%	41.82%	26.51%	94.74%	2,751.58%	332.64%	-87.16%
EBITDA Growth	437.77%	83.09%	-37.21%	27.60%	23.68%	-92.54%	-764.32%	84.16%	-22.16%	-65.14%
EBIT Growth	296.41%	76.48%	-34.75%	24.25%	22.53%	-96.87%	-645.68%	81.81%	-21.47%	-62.04%
NOPAT Growth	204.93%	50.05%	-16.64%	18.51%	20.04%	-105.33%	-100.21%	35.65%	-21.14%	-64.58%
Net Income Growth	143.89%	23.81%	-67.99%	24.43%	22.51%	-97.58%	-614.01%	81.03%	-21.47%	-62.04%
EPS Growth	140.34%	27.77%	-55.92%	27.57%	26.78%	-77.84%	-534.88%	84.34%	-5.58%	-53.39%
Operating Cash Flow Growth	58.92%	-53.99%	26.59%	-512.38%	123.54%	-17.45%	-67.53%	5.62%	-64.47%	-16.28%
Free Cash Flow Firm Growth	16.39%	-64.62%	-263.55%	149.80%	15.51%	-47.56%	-81.85%	-11.97%	-62.32%	20.63%
Invested Capital Growth	179.49%	800.27%	33.91%	-118.99%	27.66%	34.57%	133.60%	510.74%	99.98%	-77.19%
Revenue Q/Q Growth	15.95%	12.52%	6.50%	8.72%	9.09%	4.30%	9.91%	50.48%	332.64%	4,540.74%
EBITDA Q/Q Growth	77.63%	75.16%	-5.86%	23.10%	0.41%	-13.09%	-48.43%	60.30%	-9.97%	-10.76%
EBIT Q/Q Growth	101.52%	66.75%	-5.48%	21.03%	0.27%	-15.04%	-46.94%	56.29%	-9.76%	-10.14%
NOPAT Q/Q Growth	157.86%	32.92%	-0.19%	12.37%	9.54%	-14.78%	-51.10%	27.54%	-9.86%	-9.84%
Net Income Q/Q Growth	93.06%	22.42%	1.78%	13.85%	7.72%	-15.29%	-47.71%	55.98%	-9.76%	-10.14%
EPS Q/Q Growth	49.04%	25.93%	2.31%	16.53%	9.54%	-12.91%	-43.68%	58.65%	-3.78%	-7.66%
Operating Cash Flow Q/Q Growth	41.62%	7.00%	-24.05%	24.68%	-9.09%	-9.97%	-30.73%	17.78%	-25.51%	-4.05%
Free Cash Flow Firm Q/Q Growth	22.84%	-3.52%	-30.85%	144.66%	-393.80%	-7.21%	-28.39%	13.81%	-26.42%	2.09%
Invested Capital Q/Q Growth	10.15%	57.37%	39.18%	-162.41%	314.31%	-1.93%	6.28%	8.52%	-5.11%	-72.18%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	15.69%	-7.11%	-56.02%	-54.27%	-97.42%	-181.02%	-118.94%	-26.80%	-4,825.20%	-17,089.47%
Operating Margin	11.47%	-21.54%	-57.47%	-65.50%	-104.46%	-185.27%	-114.15%	-111.03%	-4,920.31%	-17,572.55%
EBIT Margin	13.71%	-10.68%	-60.51%	-59.69%	-102.40%	-187.45%	-120.45%	-31.46%	-4,930.18%	-17,560.26%
Profit (Net Income) Margin	12.37%	-43.11%	-75.40%	-59.66%	-102.60%	-187.77%	-120.23%	-32.79%	-4,930.18%	-17,560.26%
Tax Burden Percent	90.21%	103.05%	101.96%	99.96%	100.19%	100.17%	99.81%	104.24%	100.00%	100.00%
Interest Burden Percent	100.00%	391.73%	122.22%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	9.79%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	24.62%	-103.88%	0.00%	-165.80%	-92.43%	-150.98%	-120.78%	-172.94%	-1,273.35%	-585.70%
ROIC Less NNEP Spread (ROIC-NNEP)	14.86%	-24.97%	0.00%	-150.89%	-48.54%	-114.00%	-103.72%	-187.01%	-1,240.98%	-551.49%
Return on Net Nonoperating Assets (RNNOA)	-4.91%	17.73%	0.00%	116.23%	22.29%	73.69%	81.04%	163.93%	1,171.93%	485.23%
Return on Equity (ROE)	19.71%	-86.15%	-107.16%	-49.57%	-70.15%	-77.29%	-39.74%	-9.00%	-101.42%	-100.47%
Cash Return on Invested Capital (CROIC)	-69.98%	-158.80%	0.00%	0.00%	-116.73%	-180.45%	-200.87%	-316.66%	-1,340.01%	-459.99%
Operating Return on Assets (OROA)	7.22%	-4.15%	-17.99%	-13.66%	-23.01%	-41.21%	-24.58%	-5.62%	-76.59%	-77.36%
Return on Assets (ROA)	6.51%	-16.77%	-22.42%	-13.66%	-23.05%	-41.28%	-24.54%	-5.85%	-76.59%	-77.36%
Return on Common Equity (ROCE)	19.71%	-86.15%	-107.16%	-49.57%	-70.15%	-77.29%	-39.74%	-9.00%	-101.42%	-100.47%
Return on Equity Simple (ROE_SIMPLE)	15.40%	-62.37%	-182.75%	-45.13%	-72.74%	-87.40%	-35.06%	-6.42%	-79.38%	-115.59%
Net Operating Profit after Tax (NOPAT)	197	-187	-375	-322	-395	-494	-241	-120	-187	-154
NOPAT Margin	10.34%	-15.08%	-40.23%	-45.85%	-73.12%	-129.69%	-79.90%	-77.72%	-3,444.22%	-12,300.78%
Net Nonoperating Expense Percent (NNEP)	9.76%	-78.91%	-44.83%	-14.90%	-43.89%	-36.98%	-17.06%	14.08%	-32.37%	-34.20%
Return On Investment Capital (ROIC_SIMPLE)	7.38%	-8.94%	-19.46%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	29.33%	38.76%	48.38%	40.27%	58.86%	74.79%	69.02%	79.36%	1,544.90%	5,989.07%
R&D to Revenue	42.30%	70.57%	94.01%	109.87%	133.74%	192.77%	133.49%	107.84%	3,473.01%	11,683.48%
Operating Expenses to Revenue	88.53%	121.54%	157.47%	165.50%	204.46%	285.27%	214.15%	211.03%	5,020.31%	17,672.55%
Earnings before Interest and Taxes (EBIT)	261	-133	-565	-419	-553	-714	-363	-49	-267	-220
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	298	-88	-523	-381	-526	-689	-358	-41	-262	-214
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.60	10.50	29.55	8.45	17.66	11.76	7.06	4.56	4.45	9.18
Price to Tangible Book Value (P/TBV)	7.60	10.50	29.55	8.58	17.98	11.94	7.14	4.64	4.56	9.51
Price to Revenue (P/Rev)	6.11	7.26	12.19	11.17	24.91	25.26	24.22	23.26	276.22	1,393.91
Price to Earnings (P/E)	49.37	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	2.03%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	9.57	20.38	0.00	0.00	26.10	24.45	23.44	24.51	60.37	160.19
Enterprise Value to Revenue (EV/Rev)	5.92	6.90	11.71	9.72	23.16	24.10	21.72	18.93	217.72	1,249.80
Enterprise Value to EBITDA (EV/EBITDA)	37.73	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	43.19	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	57.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	116.39	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	27.47	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.74	1.44	4.01	1.18	1.30	0.83	0.41	0.55	0.05	0.12
Long-Term Debt to Equity	0.74	1.32	4.01	1.18	1.30	0.83	0.41	0.54	0.02	0.08
Financial Leverage	-0.33	-0.71	-1.12	-0.77	-0.46	-0.65	-0.78	-0.88	-0.94	-0.88
Leverage Ratio	3.03	5.14	4.78	3.63	3.04	1.87	1.62	1.54	1.32	1.30
Compound Leverage Factor	3.03	20.13	5.84	3.63	3.04	1.87	1.62	1.54	1.32	1.30
Debt to Total Capital	42.67%	59.03%	80.05%	54.17%	56.58%	45.46%	28.95%	35.32%	4.58%	10.95%
Short-Term Debt to Total Capital	0.00%	5.03%	0.00%	0.00%	0.00%	0.00%	0.00%	0.51%	2.86%	3.94%
Long-Term Debt to Total Capital	42.67%	54.00%	80.05%	54.17%	56.58%	45.46%	28.95%	34.82%	1.71%	7.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	57.33%	40.97%	19.95%	45.83%	43.42%	54.54%	71.05%	64.68%	95.42%	89.05%
Debt to EBITDA	3.81	-14.01	-2.95	-2.88	-1.89	-0.99	-1.17	-10.41	-0.06	-0.11
Net Debt to EBITDA	-1.18	4.96	0.85	2.68	1.80	0.64	2.10	16.17	1.21	0.84
Long-Term Debt to EBITDA	3.81	-12.82	-2.95	-2.88	-1.89	-0.99	-1.17	-10.26	-0.02	-0.07
Debt to NOPAT	5.78	-6.60	-4.11	-3.41	-2.51	-1.38	-1.75	-3.59	-0.09	-0.15
Net Debt to NOPAT	-1.78	2.34	1.19	3.17	2.40	0.90	3.13	5.58	1.70	1.17
Long-Term Debt to NOPAT	5.78	-6.04	-4.11	-3.41	-2.51	-1.38	-1.75	-3.54	-0.03	-0.10
Altman Z-Score	2.78	1.30	1.18	1.30	2.70	3.69	6.20	3.90	5.20	6.03
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.20	3.95	4.13	5.75	5.97	5.55	8.21	13.91	4.95	3.60
Quick Ratio	2.67	3.18	3.56	5.01	4.90	4.59	7.04	12.55	4.28	3.15
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-559	-669	-406	248	-499	-590	-400	-220	-196	-121
Operating Cash Flow to CapEx	-150.26%	-658.28%	-1,055.50%	-1,151.40%	130.73%	-765.48%	-635.51%	-1,933.30%	-4,602.51%	-4,394.74%
Free Cash Flow to Firm to Interest Expense	0.00	-1.73	-3.24	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	-1.29	-2.59	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	-1.49	-2.84	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.53	0.39	0.30	0.23	0.22	0.22	0.20	0.18	0.02	0.00
Accounts Receivable Turnover	3.80	4.04	5.08	5.52	5.62	5.44	7.67	8.91	1.18	0.39
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	6.70	6.11	5.03	3.68	3.38	3.36	4.30	3.82	0.14	0.03
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	96.17	90.26	71.91	66.13	64.95	67.05	47.60	40.96	309.89	931.14
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	96.17	90.26	71.91	66.13	64.95	67.05	47.60	40.96	309.89	931.14
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,177	421	-60	-91	479	375	279	119	20	9.78
Invested Capital Turnover	2.38	6.89	-12.35	3.62	1.26	1.16	1.51	2.23	0.37	0.05
Increase / (Decrease) in Invested Capital	756	481	31	-570	104	96	160	100	9.77	-33
Enterprise Value (EV)	11,263	8,582	10,930	6,822	12,508	9,176	6,539	2,926	1,180	1,566
Market Capitalization	11,614	9,021	11,375	7,841	13,454	9,619	7,292	3,596	1,497	1,747
Book Value per Share	$15.99	$9.19	$4.39	$10.66	$9.65	$10.98	$15.45	$12.21	$6.17	$4.20
Tangible Book Value per Share	$15.99	$9.19	$4.39	$10.49	$9.48	$10.81	$15.27	$11.99	$6.02	$4.06
Total Capital	2,665	2,097	1,929	2,025	1,754	1,500	1,453	1,220	353	214
Total Debt	1,137	1,238	1,544	1,097	992	682	421	431	16	23
Total Long-Term Debt	1,137	1,133	1,544	1,097	992	682	421	425	6.04	15
Net Debt	-351	-438	-445	-1,019	-946	-443	-753	-670	-317	-181
Capital Expenditures (CapEx)	137	76	31	38	82	60	61	12	5.34	3.40
Debt-free, Cash-free Net Working Capital (DFCFNWC)	987	355	-51	35	131	79	79	67	-20	-33
Debt-free Net Working Capital (DFNWC)	2,342	2,031	1,938	2,151	2,069	1,204	1,252	1,146	308	171
Net Working Capital (NWC)	2,342	1,926	1,938	2,151	2,069	1,204	1,252	1,140	298	162
Net Nonoperating Expense (NNE)	-39	349	328	97	159	221	121	-69	81	66
Net Nonoperating Obligations (NNO)	-351	-438	-445	-1,019	-283	-443	-753	-670	-317	-181
Total Depreciation and Amortization (D&A)	38	44	42	38	27	25	4.57	7.20	5.69	5.90
Debt-free, Cash-free Net Working Capital to Revenue	51.89%	28.54%	-5.48%	5.06%	24.18%	20.85%	26.10%	43.62%	-375.91%	-2,594.41%
Debt-free Net Working Capital to Revenue	123.12%	163.36%	207.74%	306.51%	383.11%	316.19%	416.06%	741.66%	5,684.60%	13,621.55%
Net Working Capital to Revenue	123.12%	154.88%	207.74%	306.51%	383.11%	316.19%	416.06%	737.67%	5,498.14%	12,948.84%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$2.47	($5.80)	($8.03)	($5.15)	($7.11)	($9.71)	($5.46)	($0.86)	($5.49)	($5.20)
Adjusted Weighted Average Basic Shares Outstanding	95.08M	92.40M	87.56M	87.15M	79.42M	77.78M	71.29M	64.98M	54.81M	45.67M
Adjusted Diluted Earnings per Share	$2.34	($5.80)	($8.03)	($5.15)	($7.11)	($9.71)	($5.46)	($0.86)	($5.49)	($5.20)
Adjusted Weighted Average Diluted Shares Outstanding	107.88M	92.40M	87.56M	87.15M	79.42M	77.78M	71.29M	64.98M	54.81M	45.67M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	($5.15)	($7.11)	($9.71)	($5.46)	($0.86)	($5.49)	($5.20)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	97.03M	93.86M	87.98M	81.26M	77.96M	73.62M	66.25M	58.82M	48.70M	42.29M
Normalized Net Operating Profit after Tax (NOPAT)	197	-187	-375	-322	-395	-494	-241	-120	-187	-154
Normalized NOPAT Margin	10.34%	-15.08%	-40.23%	-45.85%	-73.12%	-129.69%	-79.90%	-77.72%	-3,444.22%	-12,300.78%
Pre Tax Income Margin	13.71%	-41.83%	-73.95%	-59.69%	-102.40%	-187.45%	-120.45%	-31.46%	-4,930.18%	-17,560.26%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-0.34	-4.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	-0.48	-2.99	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	-0.54	-4.75	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	-0.68	-3.24	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Sarepta Therapeutics' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	80.15%	65.94%	40.79%	38.93%	63.10%	53.54%	44.10%	11.89%	20.24%	28.28%	21.57%
EBITDA Growth	-844.22%	252.12%	296.94%	687.82%	144.00%	153.74%	81.56%	98.12%	-49.78%	13.84%	-222.50%
EBIT Growth	-1,025.30%	325.41%	202.51%	193.09%	133.06%	137.79%	74.74%	93.09%	-44.31%	12.35%	-174.19%
NOPAT Growth	-791.29%	437.67%	250.37%	99.64%	131.47%	137.24%	84.13%	36.76%	-58.94%	-0.96%	-281.20%
Net Income Growth	-1,338.98%	248.37%	182.10%	126.98%	106.99%	141.79%	84.12%	89.66%	-392.03%	10.44%	-435.35%
EPS Growth	-1,343.24%	97.47%	173.91%	125.93%	106.31%	163.71%	84.35%	89.81%	-388.33%	13.29%	-390.00%
Operating Cash Flow Growth	-141.01%	268.41%	38.37%	112.22%	-15.61%	40.84%	-76.57%	-82.94%	-106.96%	-215.05%	47.75%
Free Cash Flow Firm Growth	-25.34%	-33.69%	-104.43%	-134.25%	-225.75%	-329.18%	-1,273.22%	-58.12%	-91.68%	-121.29%	86.98%
Invested Capital Growth	84.61%	179.49%	299.32%	625.31%	1,146.91%	800.27%	370.62%	215.42%	212.56%	33.91%	-185.16%
Revenue Q/Q Growth	13.13%	40.94%	28.72%	-12.22%	4.20%	19.58%	27.02%	3.05%	-1.91%	12.23%	-1.38%
EBITDA Q/Q Growth	-305.02%	315.86%	96.50%	-55.58%	27.36%	332.59%	-486.50%	96.68%	-18.48%	20.20%	40.05%
EBIT Q/Q Growth	-323.31%	405.04%	150.47%	-67.24%	47.82%	221.69%	-127.45%	88.37%	-17.36%	18.67%	37.79%
NOPAT Q/Q Growth	-240.43%	582.51%	6,677.39%	-101.10%	9.23%	290.88%	84.39%	3.31%	-29.26%	18.67%	37.79%
Net Income Q/Q Growth	-381.36%	373.21%	420.29%	-82.11%	-20.89%	211.53%	-71.00%	95.37%	-373.03%	57.61%	-11.34%
EPS Q/Q Growth	-394.87%	358.82%	385.71%	-81.08%	-53.16%	271.74%	-70.37%	95.39%	-372.58%	57.82%	-10.94%
Operating Cash Flow Q/Q Growth	-733.85%	230.19%	-573.16%	106.17%	-342.90%	52.35%	6.16%	41.63%	-126.64%	-42.22%	2.77%
Free Cash Flow Firm Q/Q Growth	-47.72%	22.19%	-7.14%	-1.78%	-57.56%	-18.98%	-22.77%	-41.53%	-107.59%	-280.70%	85.86%
Invested Capital Q/Q Growth	27.01%	10.15%	26.76%	4.10%	92.29%	57.37%	130.24%	78.97%	207.99%	39.18%	1.80%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-50.15%	27.67%	9.38%	6.14%	12.14%	13.04%	-6.70%	-1.45%	-45.00%	-37.26%	-52.40%
Operating Margin	-40.33%	24.56%	4.75%	-0.19%	8.44%	6.21%	-6.28%	-51.11%	-54.47%	-41.34%	-57.04%
EBIT Margin	-51.49%	26.08%	7.28%	3.74%	10.02%	10.17%	-10.00%	-5.58%	-49.46%	-41.34%	-57.04%
Profit (Net Income) Margin	-60.08%	24.16%	7.19%	1.78%	8.74%	11.51%	-12.34%	-9.16%	-203.85%	-42.27%	-111.93%
Tax Burden Percent	116.69%	92.61%	98.84%	47.58%	87.14%	113.09%	123.40%	164.14%	100.79%	107.84%	100.51%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	408.92%	94.83%	195.21%
Effective Tax Rate	0.00%	7.39%	1.16%	52.42%	12.86%	-13.09%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-54.72%	54.13%	11.53%	-0.29%	23.61%	48.35%	-57.60%	-4,625.09%	-10,271.56%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-291.32%	51.77%	7.94%	-1.87%	22.18%	44.32%	-52.47%	-4,634.66%	-10,217.78%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-27.77%	-17.11%	-2.60%	0.88%	-10.59%	-31.46%	45.06%	4,585.65%	10,170.63%	0.00%	0.00%
Return on Equity (ROE)	-82.49%	37.02%	8.94%	0.60%	13.02%	16.89%	-12.54%	-39.44%	-100.93%	-107.16%	-159.10%
Cash Return on Invested Capital (CROIC)	-66.58%	-69.98%	-108.47%	-145.51%	-181.06%	-158.80%	-241.41%	-493.71%	-822.06%	0.00%	0.00%
Operating Return on Assets (OROA)	-34.38%	13.73%	3.56%	1.72%	4.48%	3.96%	-3.53%	-1.83%	-15.78%	-12.29%	-17.18%
Return on Assets (ROA)	-40.12%	12.71%	3.52%	0.82%	3.90%	4.48%	-4.35%	-3.00%	-65.04%	-12.57%	-33.71%
Return on Common Equity (ROCE)	-82.49%	37.02%	8.94%	0.60%	13.02%	16.89%	-12.54%	-39.44%	-100.93%	-107.16%	-159.10%
Return on Equity Simple (ROE_SIMPLE)	-21.74%	0.00%	9.98%	4.39%	1.76%	0.00%	-90.39%	-122.43%	-156.47%	0.00%	-166.24%
Net Operating Profit after Tax (NOPAT)	-210	150	22	-0.33	30	28	-15	-93	-97	-75	-92
NOPAT Margin	-28.23%	22.74%	4.70%	-0.09%	7.36%	7.02%	-4.40%	-35.78%	-38.13%	-28.94%	-39.93%
Net Nonoperating Expense Percent (NNEP)	236.60%	2.36%	3.60%	1.58%	1.43%	4.03%	-5.13%	9.57%	-53.78%	-4.71%	-32.07%
Return On Investment Capital (ROIC_SIMPLE)	-9.22%	5.62%	-	-	-	1.33%	-	-	-	-3.88%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	17.94%	24.89%	27.44%	38.24%	30.72%	33.19%	36.43%	45.39%	43.67%	46.62%	45.51%
R&D to Revenue	103.84%	30.37%	48.05%	49.51%	48.47%	49.28%	58.56%	92.59%	96.91%	82.73%	94.11%
Operating Expenses to Revenue	140.33%	75.44%	95.25%	100.19%	91.56%	93.79%	106.28%	151.11%	154.47%	141.34%	157.04%
Earnings before Interest and Taxes (EBIT)	-384	172	34	14	41	40	-33	-15	-125	-107	-131
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-374	182	44	22	50	52	-22	-3.79	-114	-96	-121
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.42	7.60	9.75	13.87	12.60	10.50	14.79	14.39	17.01	29.55	22.47
Price to Tangible Book Value (P/TBV)	5.42	7.60	9.75	13.87	12.60	10.50	14.79	14.39	17.01	29.55	23.17
Price to Revenue (P/Rev)	2.77	6.11	7.26	9.92	8.63	7.26	10.23	10.63	12.43	12.19	11.05
Price to Earnings (P/E)	0.00	49.37	95.28	313.79	716.73	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	2.03%	1.05%	0.32%	0.14%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	4.38	9.57	11.00	17.44	14.77	20.38	40.40	86.41	176.77	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	2.93	5.92	7.17	9.77	8.52	6.90	9.78	10.01	11.76	11.71	10.44
Enterprise Value to EBITDA (EV/EBITDA)	0.00	37.73	69.97	144.14	157.57	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	43.19	90.86	236.26	351.12	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	57.25	154.11	509.11	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.00	0.74	1.01	1.14	1.29	1.44	1.62	1.67	1.73	4.01	3.58
Long-Term Debt to Equity	1.00	0.74	0.93	1.05	1.18	1.32	1.62	1.67	1.73	4.01	3.58
Financial Leverage	0.10	-0.33	-0.33	-0.47	-0.48	-0.71	-0.86	-0.99	-1.00	-1.12	-1.15
Leverage Ratio	3.18	3.03	3.38	3.60	3.75	5.14	5.24	4.17	3.90	4.78	6.46
Compound Leverage Factor	3.18	3.03	3.38	3.60	3.75	5.14	5.24	4.17	15.93	4.53	12.61
Debt to Total Capital	49.90%	42.67%	50.13%	53.24%	56.32%	59.03%	61.80%	62.50%	63.39%	80.05%	78.17%
Short-Term Debt to Total Capital	0.00%	0.00%	3.74%	3.97%	4.80%	5.03%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	49.90%	42.67%	46.39%	49.27%	51.52%	54.00%	61.80%	62.50%	63.39%	80.05%	78.17%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	50.10%	57.33%	49.87%	46.76%	43.68%	40.97%	38.20%	37.50%	36.61%	19.95%	21.83%
Debt to EBITDA	-9.09	3.81	7.31	12.02	16.33	-14.01	-3.48	-2.65	-2.26	-2.95	-3.12
Net Debt to EBITDA	-2.81	-1.18	-0.91	-2.30	-2.00	4.96	1.40	1.34	1.19	0.85	1.07
Long-Term Debt to EBITDA	-9.09	3.81	6.76	11.13	14.94	-12.82	-3.48	-2.65	-2.26	-2.95	-3.12
Debt to NOPAT	-13.87	5.78	16.09	42.47	-26.34	-6.60	-4.42	-3.46	-3.00	-4.11	-4.12
Net Debt to NOPAT	-4.29	-1.78	-2.00	-8.11	3.22	2.34	1.78	1.75	1.58	1.19	1.41
Long-Term Debt to NOPAT	-13.87	5.78	14.89	39.30	-24.10	-6.04	-4.42	-3.46	-3.00	-4.11	-4.12
Altman Z-Score	0.63	2.71	2.45	3.17	2.46	1.47	1.96	1.75	2.02	1.67	1.35
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.02	4.20	3.84	3.90	4.05	3.95	5.44	4.96	4.63	4.13	4.36
Quick Ratio	1.95	2.67	2.33	2.64	2.91	3.18	4.55	4.21	3.92	3.56	3.77
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-895	-606	-779	-727	-714	-453	-381	-310	-219	-106	-28
Operating Cash Flow to CapEx	-1,336.59%	241.70%	-189.73%	51.23%	-746.13%	-287.08%	-386.57%	-682.53%	-2,207.65%	-1,160.12%	-789.26%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.57	0.00	-0.22
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.54	0.00	-0.52
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.57	0.00	-0.58
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.67	0.53	0.49	0.46	0.45	0.39	0.35	0.33	0.32	0.30	0.30
Accounts Receivable Turnover	4.30	3.80	4.35	5.04	4.66	4.04	4.25	4.55	4.85	5.08	4.99
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	7.32	6.70	6.33	6.47	6.49	6.11	5.62	5.39	5.27	5.03	4.61
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	84.83	96.17	83.82	72.37	78.37	90.26	85.94	80.15	75.20	71.91	73.18
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	84.83	96.17	83.82	72.37	78.37	90.26	85.94	80.15	75.20	71.91	73.18
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,495	1,177	1,068	843	810	421	268	116	65	-60	-99
Invested Capital Turnover	1.94	2.38	2.46	3.14	3.21	6.89	13.10	129.28	269.38	-12.35	-13.12
Increase / (Decrease) in Invested Capital	685	756	801	727	745	481	366	217	123	31	-64
Enterprise Value (EV)	6,545	11,263	11,758	14,701	11,959	8,582	10,810	10,042	11,479	10,930	9,150
Market Capitalization	6,193	11,614	11,910	14,935	12,111	9,021	11,307	10,667	12,127	11,375	9,680
Book Value per Share	$11.78	$15.99	$12.80	$11.39	$10.23	$9.19	$8.19	$7.96	$8.10	$4.39	$4.92
Tangible Book Value per Share	$11.78	$15.99	$12.80	$11.39	$10.23	$9.19	$8.19	$7.96	$8.10	$4.39	$4.77
Total Capital	2,281	2,665	2,449	2,303	2,200	2,097	2,001	1,977	1,947	1,929	1,974
Total Debt	1,138	1,137	1,228	1,226	1,239	1,238	1,237	1,236	1,234	1,544	1,543
Total Long-Term Debt	1,138	1,137	1,136	1,135	1,134	1,133	1,237	1,236	1,234	1,544	1,543
Net Debt	352	-351	-153	-234	-151	-438	-497	-625	-648	-445	-530
Capital Expenditures (CapEx)	44	38	37	29	32	19	30	18	9.49	7.96	8.23
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1,304	987	879	626	571	355	267	113	69	-51	-49
Debt-free Net Working Capital (DFNWC)	1,827	2,342	2,077	2,087	1,962	2,031	2,000	1,974	1,951	1,938	2,023
Net Working Capital (NWC)	1,827	2,342	1,986	1,995	1,856	1,926	2,000	1,974	1,951	1,938	2,023
Net Nonoperating Expense (NNE)	237	-9.32	-12	-6.79	-5.70	-18	26	-70	420	34	166
Net Nonoperating Obligations (NNO)	352	-351	-153	-234	-151	-438	-497	-625	-648	-445	-530
Total Depreciation and Amortization (D&A)	9.98	10	9.81	8.72	8.74	11	11	11	11	11	11
Debt-free, Cash-free Net Working Capital to Revenue	58.40%	51.89%	53.59%	41.61%	40.69%	28.54%	24.12%	11.29%	7.11%	-5.48%	-5.65%
Debt-free Net Working Capital to Revenue	81.80%	123.12%	126.65%	138.65%	139.79%	163.36%	181.01%	196.72%	200.01%	207.74%	230.93%
Net Working Capital to Revenue	81.80%	123.12%	121.06%	132.57%	132.27%	154.88%	181.01%	196.72%	200.01%	207.74%	230.93%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($4.60)	$1.67	$0.35	$0.07	$0.38	$0.79	($0.46)	($0.27)	($5.86)	($1.24)	($2.94)
Adjusted Weighted Average Basic Shares Outstanding	97.36M	95.08M	95.39M	94.62M	93.99M	92.40M	88.89M	88.74M	88.19M	87.56M	87.63M
Adjusted Diluted Earnings per Share	($4.60)	$1.56	$0.34	$0.07	$0.37	$0.79	($0.46)	($0.27)	($5.86)	($1.24)	($2.94)
Adjusted Weighted Average Diluted Shares Outstanding	97.36M	107.88M	100.45M	99.14M	99.11M	92.40M	88.89M	88.74M	88.19M	87.56M	87.63M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	98.28M	97.03M	95.52M	95.37M	94.52M	93.86M	93.55M	93.28M	93.15M	87.98M	87.78M
Normalized Net Operating Profit after Tax (NOPAT)	-210	150	22	-0.49	30	17	-15	-93	-97	-75	-92
Normalized NOPAT Margin	-28.23%	22.74%	4.70%	-0.14%	7.36%	4.34%	-4.40%	-35.78%	-38.13%	-28.94%	-39.93%
Pre Tax Income Margin	-51.49%	26.08%	7.28%	3.74%	10.02%	10.17%	-10.00%	-5.58%	-202.25%	-39.20%	-111.36%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.32	0.00	-1.05
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.25	0.00	-0.73
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.35	0.00	-1.11
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.27	0.00	-0.80
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Sarepta Therapeutics' Financials

When does Sarepta Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Sarepta Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Sarepta Therapeutics' net income changed over the last 9 years?

Over the last 9 years, Sarepta Therapeutics' net income changed from -$220.03 million in 2015 to $235.24 million in 2024, a change of -206.9%. View Sarepta Therapeutics' forecast to see where analysts expect Sarepta Therapeutics to go next.

What is Sarepta Therapeutics's operating income?

Sarepta Therapeutics's total operating income in 2024 was $218.08 million, based on the following breakdown:

Total Gross Profit: $1.90 billion
Total Operating Expenses: $1.68 billion

How has Sarepta Therapeutics revenue changed over the last 9 years?

Over the last 9 years, Sarepta Therapeutics' total revenue changed from $1.25 million in 2015 to $1.90 billion in 2024, a change of 151,694.0%.

How much debt does Sarepta Therapeutics have?

Sarepta Therapeutics' total liabilities were at $2.44 billion at the end of 2024, a 1.3% increase from 2023, and a 2,819.0% increase since 2015.

How much cash does Sarepta Therapeutics have?

In the past 9 years, Sarepta Therapeutics' cash and equivalents has ranged from $80.30 million in 2015 to $2.12 billion in 2021, and is currently $1.10 billion as of their latest financial filing in 2024.

How has Sarepta Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, Sarepta Therapeutics' book value per share changed from 4.20 in 2015 to 15.99 in 2024, a change of 280.4%.

Related Companies

This page (NASDAQ:SRPT) was last updated on 5/28/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sarepta Therapeutics (SRPT) Financials

Frequently Asked Questions About Sarepta Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sarepta Therapeutics (SRPT) Financials

Annual Income Statements for Sarepta Therapeutics

Quarterly Income Statements for Sarepta Therapeutics

Annual Cash Flow Statements for Sarepta Therapeutics

Quarterly Cash Flow Statements for Sarepta Therapeutics

Annual Balance Sheets for Sarepta Therapeutics

Quarterly Balance Sheets for Sarepta Therapeutics

Annual Metrics And Ratios for Sarepta Therapeutics

Quarterly Metrics And Ratios for Sarepta Therapeutics

Frequently Asked Questions About Sarepta Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools